1. Home
  2. HDL vs IRWD Comparison

HDL vs IRWD Comparison

Compare HDL & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

N/A

Current Price

$10.68

Market Cap

781.1M

ML Signal

N/A

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

N/A

Current Price

$3.76

Market Cap

687.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HDL
IRWD
Founded
2016
1998
Country
Singapore
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.1M
687.4M
IPO Year
2023
2009

Fundamental Metrics

Financial Performance
Metric
HDL
IRWD
Price
$10.68
$3.76
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
★ $17.93
$6.10
AVG Volume (30 Days)
737.0
★ 1.5M
Earning Date
08-26-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1400.00
EPS
N/A
★ 0.55
Revenue
N/A
★ $298,276,000.00
Revenue This Year
$9.19
$59.19
Revenue Next Year
$14.22
$4.80
P/E Ratio
$55.56
★ $7.49
Revenue Growth
N/A
★ 8.88
52 Week Low
$11.55
$1.41
52 Week High
$18.51
$5.78

Technical Indicators

Market Signals
Indicator
HDL
IRWD
Relative Strength Index (RSI) 34.38 40.20
Support Level N/A $3.89
Resistance Level $13.87 $3.96
Average True Range (ATR) 0.14 0.19
MACD -0.12 -0.04
Stochastic Oscillator 0.00 7.28

Price Performance

Historical Comparison
HDL
IRWD

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: